While others have shown PD-L1 expression on the surface of CTCs in other solid tumors including prostate cancer [14, 15, 50–52], we have detected 4 different checkpoint ligands PD-L1, PD-L2, B7-H3, and CTLA-4 on CTCs. This evidence concerns the gene CD276 and prostate carcinoma.